

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6990)**

## **DISCLOSEABLE TRANSACTION SUBSCRIPTION FOR WEALTH MANAGEMENT PRODUCT**

### **WEALTH MANAGEMENT PRODUCTS WITH BOC**

References are made to the April 2026 Announcement and the June 2026 Announcement in relation to, among others, the BOC Structured Deposit Agreement and the BOC Structured Deposit Agreement II.

On August 4, 2026, the Company entered into the BOC Structured Deposit Agreement III, pursuant to which the Company agreed to subscribe for the BOC Structured Deposit III in the principal amount of RMB400 million.

As at the date of this announcement, the outstanding principal amount of the wealth management products that the Company maintained at BOC is RMB1,100 million, comprising (i) the BOC Structured Deposit in the principal amount of RMB300 million pursuant to the BOC Structured Deposit Agreement, (ii) the BOC Structured Deposit II in the principal amount of RMB400 million pursuant to the BOC Structured Deposit Agreement II, and (iii) the BOC Structured Deposit III in the principal amount of RMB400 million pursuant to the BOC Structured Deposit Agreement III.

### **LISTING RULES IMPLICATIONS**

As the highest applicable percentage ratio (as defined under the Listing Rules) of the outstanding amount of the wealth management products maintained at BOC as at the date of this announcement exceeds 5% but is less than 25%, the subscriptions for the BOC Structured Deposits constitute a discloseable transaction of the Company under the Listing Rules, and are subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules.

## **WEALTH MANAGEMENT PRODUCTS WITH BOC**

References are made to the April 2026 Announcement and the June 2026 Announcement in relation to, among others, the BOC Structured Deposit Agreement and the BOC Structured Deposit Agreement II.

On August 4, 2026, the Company entered into the BOC Structured Deposit Agreement III, pursuant to which the Company agreed to subscribe for the BOC Structured Deposit III in the principal amount of RMB400 million.

As at the date of this announcement, the outstanding principal amount of the wealth management product that the Company maintained at BOC is RMB1,100 million, comprising (i) the BOC Structured Deposit in the principal amount of RMB300 million pursuant to the BOC Structured Deposit Agreement, (ii) the BOC Structured Deposit II in the principal amount of RMB400 million pursuant to the BOC Structured Deposit Agreement II, and (iii) the BOC Structured Deposit III in the principal amount of RMB400 million pursuant to the BOC Structured Deposit Agreement III.

For the principal terms of the BOC Structured Deposit Agreement, please refer to the section headed “WEALTH MANAGEMENT PRODUCTS WITH BOC – The BOC Structured Deposit Agreement” in the April 2026 Announcement.

For the principal terms of the BOC Structured Deposit Agreement II, please refer to the section headed “WEALTH MANAGEMENT PRODUCTS WITH BOC – The BOC Structured Deposit Agreement II” in the June 2026 Announcement.

The principal terms of the BOC Structured Deposit Agreement III are set out as follows:

### **The BOC Structured Deposit Agreement III**

|                                             |                                           |
|---------------------------------------------|-------------------------------------------|
| <b>Date of agreement</b>                    | August 4, 2026                            |
| <b>Parties</b>                              | (1) the Company; and<br>(2) BOC           |
| <b>Name of the Structured Deposit</b>       | RMB Structured Deposit (人民幣結構性存款)         |
| <b>Type of the Structured Deposit</b>       | Principal-guaranteed with floating return |
| <b>Principal amount of the subscription</b> | RMB400 million                            |

|                                                    |                                                                                                                                                                                                                               |
|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Commencement date</b>                           | August 6, 2026                                                                                                                                                                                                                |
| <b>Maturity date</b>                               | February 18, 2027                                                                                                                                                                                                             |
| <b>Term of the Structured Deposit</b>              | 196 days                                                                                                                                                                                                                      |
| <b>Expected annualized floating rate of return</b> | 0.80% or 1.925% per annum                                                                                                                                                                                                     |
| <b>Subject linked</b>                              | The USD/JPY spot exchange rate published on the Bloomberg “JPY Curncy QR” Page                                                                                                                                                |
| <b>Early termination</b>                           | Neither the Company nor BOC has the right to terminate the BOC Structured Deposit Agreement III early, except where there is significant change in laws and regulations or force majeure which necessitates such termination. |
| <b>Redemption and Payment</b>                      | The Company has no right to redeem the structured deposit during its term. The principal and the actual return of the structured deposit will be paid in one lump sum upon its maturity or early termination by BOC.          |

The Directors are of the view that the consideration of the subscription for the BOC Structured Deposits was determined on the basis of arm’s length commercial terms. The BOC Structured Deposits were subscribed for by the Company by using the idle own funds of the Group and without using the proceeds from the initial public offering of the Company, the placing of new H shares of the Company which was completed on May 16, 2024, the subscription of new domestic shares of the Company which was completed on December 18, 2024, the placing of new H shares of the Company which was completed on June 12, 2025 or the placing of new H shares of the Company which was completed on July 10, 2026.

## **INFORMATION OF THE PARTIES**

The Company is a biopharmaceutical company, principally engaged in the R&D, manufacturing and commercialization of novel drugs in oncology, immunology and other therapeutic areas.

BOC is a joint stock company incorporated in the PRC with limited liability. BOC is listed on The Stock Exchange of Hong Kong Limited (stock code: 3988) and the Shanghai Stock Exchange (stock code: 601988). BOC is principally engaged in the commercial banking business which provides services such as accepting deposits, making loans and offering basic investment products.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, BOC and its ultimate beneficial owner are third parties independent of the Company and its connected persons as of the date of this announcement.

## **REASONS FOR AND BENEFITS OF THE SUBSCRIPTIONS FOR THE WEALTH MANAGEMENT PRODUCTS**

The Directors are of the view that taking into account, among others, (i) the nature of the principal-guaranteed wealth management products with floating return, (ii) the expected rate of return, and (iii) the mid-to-short term nature of the wealth management products, the subscriptions for BOC Structured Deposits by using the idle own funds of the Group will have higher returns on deposits than those generally available from commercial banks and are conducive to improving the efficiency of the use of the Group's idle funds. The Directors believe that the terms of BOC Structured Deposits are fair and reasonable and in the interests of the Company's shareholders as a whole.

## **LISTING RULES IMPLICATIONS**

As the highest applicable percentage ratio (as defined under the Listing Rules) of the outstanding amount of the wealth management products maintained at BOC as at the date of this announcement exceeds 5% but is less than 25%, the subscriptions for BOC Structured Deposits constitute a discloseable transaction of the Company under the Listing Rules, and are subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules.

## **DEFINITIONS**

|                           |                                                                                                                                                                                                                                                             |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “April 2026 Announcement” | The announcement of the Company dated April 15, 2026, in relation to subscriptions for wealth management products                                                                                                                                           |
| “Board”                   | the board of directors of the Company                                                                                                                                                                                                                       |
| “BOC”                     | Bank of China Limited (中國銀行股份有限公司), a joint stock company incorporated in the PRC with limited liability, the shares of which are listed on the Shanghai Stock Exchange (stock code: 601988) and The Stock Exchange of Hong Kong Limited (stock code: 3988) |
| “BOC Structured Deposit”  | the structured deposit issued by BOC in the principal amount of RMB300 million in accordance with the terms of the BOC Structured Deposit Agreement                                                                                                         |

|                                        |                                                                                                                                                                                                                                                            |
|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “BOC Structured Deposit II”            | the structured deposit issued by BOC in the principal amount of RMB400 million in accordance with the terms of the BOC Structured Deposit Agreement II                                                                                                     |
| “BOC Structured Deposit III”           | the structured deposit issued by BOC in the principal amount of RMB400 million in accordance with the terms of the BOC Structured Deposit Agreement III                                                                                                    |
| “BOC Structured Deposits”              | BOC Structured Deposit, BOC Structured Deposit II and BOC Structured Deposit III                                                                                                                                                                           |
| “BOC Structured Deposit Agreement”     | the structured deposit product agreement entered into between the Company and BOC on April 15, 2026, the principal terms of which are set out in the April 2026 Announcement                                                                               |
| “BOC Structured Deposit Agreement II”  | the structured deposit product agreement entered into between the Company and BOC on June 30, 2026, the principal terms of which are set out in the section headed “The BOC Structured Deposit Agreement II” in the June 2026 Announcement                 |
| “BOC Structured Deposit Agreement III” | the structured deposit product agreement entered into between the Company and BOC on August 4, 2026, the principal terms of which are set out in the section headed “The BOC Structured Deposit Agreement III” in this announcement                        |
| “Company”                              | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (四川科倫博泰生物醫藥股份有限公司), a joint stock company incorporated in the PRC with limited liability, the shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 6990) |
| “Director(s)”                          | the director(s) of the Company                                                                                                                                                                                                                             |
| “Group”                                | the Company and its subsidiaries                                                                                                                                                                                                                           |
| “June 2026 Announcement”               | The announcement of the Company dated June 30, 2026, in relation to subscriptions for wealth management products                                                                                                                                           |

|                 |                                                                                                                                                                                                             |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Listing Rules” | the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time)                                                                                     |
| “PRC”           | the People’s Republic of China, which for the purpose of this announcement, shall not include Hong Kong Special Administrative Region of the PRC, Macau Special Administrative Region of the PRC and Taiwan |
| “RMB”           | Renminbi, the lawful currency of the PRC                                                                                                                                                                    |
| “%”             | per cent                                                                                                                                                                                                    |

By order of the Board  
**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**  
*Chairman of the Board and Non-executive Director*

Hong Kong, August 4, 2026

*As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.*